Theralink Technologies, Inc.
THER
$0.00
$0.000.00%
OTC PK
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 16.76% | 6.85% | 107.39% | 48.40% | -5.32% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 16.76% | 6.85% | 107.39% | 48.40% | -5.32% |
| Cost of Revenue | -24.83% | -44.41% | -23.84% | 2.45% | 9.87% |
| Gross Profit | 78.78% | 97.66% | 1,183.33% | 125.73% | -21.51% |
| SG&A Expenses | -37.92% | -22.79% | 146.91% | 141.76% | 132.51% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -37.60% | -23.43% | 138.05% | 134.95% | 126.35% |
| Operating Income | 39.91% | 24.91% | -139.95% | -142.27% | -140.54% |
| Income Before Tax | 71.69% | -142.56% | -639.14% | -801.07% | -757.01% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 71.69% | -142.56% | -639.14% | -801.07% | -757.01% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 71.69% | -142.56% | -639.14% | -801.07% | -757.01% |
| EBIT | 39.91% | 24.91% | -139.95% | -142.27% | -140.54% |
| EBITDA | 40.60% | 25.48% | -144.53% | -147.07% | -145.54% |
| EPS Basic | 71.43% | -138.10% | -457.14% | -576.92% | -492.31% |
| Normalized Basic EPS | 69.77% | -78.57% | -437.50% | -614.29% | -514.29% |
| EPS Diluted | 61.04% | -176.19% | -514.29% | -576.92% | -492.31% |
| Normalized Diluted EPS | 60.47% | -107.14% | -487.50% | -614.29% | -514.29% |
| Average Basic Shares Outstanding | 1.94% | 4.52% | 8.83% | 10.93% | 10.18% |
| Average Diluted Shares Outstanding | 64.06% | 68.21% | 74.68% | 10.93% | 10.18% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | 0.99% | 0.93% | 0.73% |